Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.
The Nasdaq-traded company is working with advisers on a strategic review after drawing interest from U.S. and European pharmaceutical giants seeking to expand in cancer therapies in the world’s second-largest economy, the people said.
